<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01247870</url>
  </required_header>
  <id_info>
    <org_study_id>10.0086</org_study_id>
    <secondary_id>2010-020818-28</secondary_id>
    <nct_id>NCT01247870</nct_id>
  </id_info>
  <brief_title>Metformin in Chronic Obstructive Pulmonary Disease</brief_title>
  <official_title>A Randomised, Double-blind, Placebo-controlled Trial of Metformin in Chronic Obstructive Pulmonary Disease (COPD) Exacerbations: a Pilot Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>St George's, University of London</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Medical Research Council</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>British Lung Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>St George's, University of London</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the effect of a tablet medication, called&#xD;
      metformin, in flare-ups (exacerbations) of chronic obstructive pulmonary disease. The&#xD;
      investigators believe that metformin may effectively control the blood sugar level during&#xD;
      COPD exacerbations. This is important because there is evidence that a high blood sugar level&#xD;
      during exacerbations may be linked with a worse prognosis. The investigators also think that&#xD;
      metformin may have other potentially useful effects on inflammation, antioxidant levels, the&#xD;
      effectiveness of steroid treatment, and recovery.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Does metformin lower the blood sugar level in patients suffering from exacerbations of&#xD;
      chronic obstructive pulmonary disease (COPD)?&#xD;
&#xD;
      COPD is the fourth leading cause of death worldwide, and a major cause of ill health. In the&#xD;
      UK, it affects some 3.7 million people and causes over 30,000 deaths per year. It is usually,&#xD;
      but not always, caused by smoking. Most people affected are over 65-years-old. Sufferers&#xD;
      experience progressively worsening cough, sputum production, breathlessness and exercise&#xD;
      limitation. This is punctuated by 'flare-ups' (exacerbations), when their symptoms worsen&#xD;
      substantially. Approximately 25% of patients hospitalised for exacerbations die within a&#xD;
      year, and over 50% within 5 years. There is a pressing need for new and improved treatments&#xD;
      for COPD exacerbations.&#xD;
&#xD;
      This study will assess the effect of metformin, a tablet medication, in COPD exacerbations.&#xD;
      Metformin has been in common use for over 50 years in patients with diabetes, to lower the&#xD;
      blood sugar level. In COPD exacerbations, the blood sugar level is often high, and the higher&#xD;
      it is, the more likely the patient will have a poor outcome. This led us to speculate that&#xD;
      lowering the sugar level with metformin may improve outcomes from COPD exacerbations.&#xD;
      However, COPD and diabetes are quite different diseases, and the investigators do not know&#xD;
      whether metformin will work as a sugar-lowering medicine in COPD exacerbations. The&#xD;
      investigators need to confirm this before the investigators can perform larger studies to&#xD;
      assess its effect on outcomes such as readmission and mortality rates.&#xD;
&#xD;
      The investigators will test this medicine in a 1-month trial in patients hospitalised for&#xD;
      COPD exacerbations. The target sample size is 69 patients, with a minimum of 48 patients&#xD;
      required for primary endpoint analysis. Two-thirds of the patients will take metformin, and&#xD;
      one-third a dummy (placebo) tablet. Neither the patients nor the researchers know who is&#xD;
      taking which. The investigators will measure their sugar levels by regular finger-prick&#xD;
      tests, and then compare the average readings in the two groups. The investigators will also&#xD;
      assess the medicine's effects on other markers of blood sugar level, and carry out additional&#xD;
      exploratory investigations on the effect of the medicine on clinical outcomes, markers of&#xD;
      inflammation, and markers of oxidative/carbonyl stress and steroid responsiveness.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2011</start_date>
  <completion_date type="Actual">May 2014</completion_date>
  <primary_completion_date type="Actual">March 2014</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Capillary glucose concentration</measure>
    <time_frame>During hospitalisation period</time_frame>
    <description>The mean capillary glucose concentration during hospitalisation period following study entry, as a measure of both efficacy and safety.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>COPD Assessment Test score</measure>
    <time_frame>Study entry, hospital discharge, and follow-up</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Exacerbation of Chronic Pulmonary Disease Tool (EXACT) score</measure>
    <time_frame>Days 5, 10 and 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to discharge</measure>
    <time_frame>Hospital discharge</time_frame>
    <description>Number of days from hospital admission to hospital discharge</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Recurrent exacerbation, readmission, and death rate</measure>
    <time_frame>3 months</time_frame>
    <description>Rates of recurrent exacerbation (defined as treatment with antibiotics and/or systemic corticosteroids for breathlessness, cough or wheeze), readmission to hospital, or death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Insulin requirement during hospitalisation period</measure>
    <time_frame>During hospitalisation period following study entry</time_frame>
    <description>Mean daily insulin use during hospitalisation period following study entry</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Haemoglobin A1c</measure>
    <time_frame>Follow-up (one month post study entry)</time_frame>
    <description>Mean haemoglobin A1c concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>C-reactive protein concentration</measure>
    <time_frame>Days 7 and follow-up (one month)</time_frame>
    <description>Mean concentration of C-reactive protein in the blood</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Body mass index</measure>
    <time_frame>Follow-up (one month)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Waist circumference</measure>
    <time_frame>Follow-up (one month)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Forced expiratory volume in 1 second</measure>
    <time_frame>At hospital discharge and follow-up (one month)</time_frame>
    <description>Mean forced expiratory volume in 1 second (FEV1) expressed as a percentage of predicted value</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fructosamine</measure>
    <time_frame>At hospital discharge and follow-up (one month)</time_frame>
    <description>Mean serum fructosamine concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Interleukin 6</measure>
    <time_frame>At hospital discharge and follow-up (one month)</time_frame>
    <description>Serum concentration of IL-6 (absolute value and change from baseline)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Interleukin 8</measure>
    <time_frame>At hospital discharge and follow-up (one month)</time_frame>
    <description>Serum concentration of IL-8 (absolute value and change from baseline)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tumor necrosis factor alpha</measure>
    <time_frame>At hospital discharge and follow-up (one month)</time_frame>
    <description>Serum concentration of TNF-alpha (absolute value and change from baseline)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Interferon gamma</measure>
    <time_frame>At hospital discharge and follow-up (one month)</time_frame>
    <description>Serum concentration of IFN-gamma (absolute value and change from baseline)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>8-isoprostane</measure>
    <time_frame>At hospital discharge and follow-up (one month)</time_frame>
    <description>Serum concentration of 8-isoprostane (absolute value and change from baseline)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total carbonyl stress</measure>
    <time_frame>At hospital discharge and follow-up (one month)</time_frame>
    <description>Total carbonyl stress, measured in serum (absolute value and change from baseline)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Glutathione reduced vs oxidised</measure>
    <time_frame>At hospital discharge and follow-up (one month)</time_frame>
    <description>Glutathione reduced vs oxidised, measured in serum (absolute value and change from baseline)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">52</enrollment>
  <condition>Chronic Obstructive Pulmonary Disease</condition>
  <arm_group>
    <arm_group_label>Metformin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Metformin 1 g twice daily for 28-35 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Matched placebo capsules</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metformin</intervention_name>
    <description>Metformin 1 g twice daily for 28-35 days</description>
    <arm_group_label>Metformin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Diagnosis of COPD&#xD;
&#xD;
          -  Hospitalisation for exacerbation of COPD&#xD;
&#xD;
          -  Age â‰¥35 years&#xD;
&#xD;
          -  Expected to remain in hospital for at least 48 hours&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Prior diagnosis of diabetes mellitus requiring insulin or oral hypoglycaemic therapy&#xD;
&#xD;
          -  Hypersensitivity to metformin hydrochloride or to any of the excipients&#xD;
&#xD;
          -  Renal impairment&#xD;
&#xD;
          -  Severe sepsis&#xD;
&#xD;
          -  Metabolic acidosis&#xD;
&#xD;
          -  Decompensated type 2 respiratory failure&#xD;
&#xD;
          -  Severe congestive cardiac failure&#xD;
&#xD;
          -  Acute coronary syndrome&#xD;
&#xD;
          -  Hepatic insufficiency&#xD;
&#xD;
          -  Excessive alcohol consumption&#xD;
&#xD;
          -  Malnourished or at high risk for malnutrition&#xD;
&#xD;
          -  Moribund or not for active treatment&#xD;
&#xD;
          -  Admitted to critical care unit&#xD;
&#xD;
          -  Unable to give informed consent&#xD;
&#xD;
          -  Pregnancy or lactation&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>35 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Emma H Baker, MBChB PhD</last_name>
    <role>Study Chair</role>
    <affiliation>St George's, University of London</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Andrew W Hitchings, BSc MBBS</last_name>
    <role>Principal Investigator</role>
    <affiliation>St George's Healthcare NHS Trust</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>North Tees and Hartlepool NHS Trust</name>
      <address>
        <city>Hartlepool</city>
        <state>Cleveland</state>
        <zip>TS24 9AH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospitals of Morecambe Bay NHS Trust</name>
      <address>
        <city>Lancaster</city>
        <state>Cumbria</state>
        <zip>LA9 7RG</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>East Sussex Healthcare NHS Trust</name>
      <address>
        <city>Hastings</city>
        <state>East Sussex</state>
        <zip>TN37 7PT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Blackpool Teaching Hospitals NHS Trust</name>
      <address>
        <city>Blackpool</city>
        <state>Lancashire</state>
        <zip>FY3 8NR</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lancashire Teaching Hospitals NHS Trust</name>
      <address>
        <city>Preston</city>
        <state>Lancashire</state>
        <zip>PR2 9HT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sherwood Forest Hospitals NHS Trust</name>
      <address>
        <city>Sutton-in-Ashfield</city>
        <state>Nottinghamshire</state>
        <zip>NG17 4JL</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chelsea and Westminster Hospital</name>
      <address>
        <city>London</city>
        <zip>SW10 9NH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St George's Hospital</name>
      <address>
        <city>London</city>
        <zip>SW17 0QT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Freeman Hospital</name>
      <address>
        <city>Newcastle</city>
        <zip>NE7 7DN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>May 2015</verification_date>
  <study_first_submitted>November 23, 2010</study_first_submitted>
  <study_first_submitted_qc>November 23, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 24, 2010</study_first_posted>
  <last_update_submitted>May 6, 2015</last_update_submitted>
  <last_update_submitted_qc>May 6, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 7, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Chronic obstructive pulmonary disease, COPD, metformin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Diseases</mesh_term>
    <mesh_term>Lung Diseases, Obstructive</mesh_term>
    <mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metformin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

